查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087626

旅行疫苗市場：按疫苗類型、劑型、年齡層和最終用戶分類的全球市場預測 – 2026-2032 年

Travel Vaccines Market by Vaccine Type, Form, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，旅行疫苗市場規模將達到 105.3 億美元，複合年成長率為 9.29%。

主要市場統計數據
基準年 2025 56.5億美元
預計年份：2026年 61.6億美元
預測年份 2032 105.3億美元
複合年成長率 (%) 9.29%

旅行疫苗是預防醫學中至關重要的領域，在旅行診所、醫院、職業健康機構和藥房等機構開展的免疫接種計畫中發揮重要作用。國際旅行的復甦、目的地特定疾病的暴露風險、入境要求的變化以及消費者對黃熱病、傷寒、甲型肝炎、乙型肝炎、日本腦炎、狂犬病、病菌感染病、霍亂和季節性流感等疫苗可預防疾病的認知不斷提高，都推動了疫苗需求的成長。

對於醫療服務提供者而言，最大的商機不再局限於出發前疫苗接種。成熟的醫療機構正在建立全面的旅行健康服務，將基於行程的風險評估、疫苗接種記錄核實、數位化提醒、文件支援、不利事件監測和旅行後護理融為一體。這種一體化模式提高了患者的依從性，並在便利性、臨床準確性、低溫運輸可靠性和檢驗公共衛生機構的指導至關重要的市場中佔據了有利地位。

旅行疫苗領域的變革

隨著疫情造成的混亂局面逐漸解除，國際旅行逐漸恢復正常，邊境衛生監測力度加大，人們更加關注感染疾病疫情透過旅行網路在區域間傳播的可能性，旅行疫苗接種行業的格局正在發生巨大變化。美國疾病管制與預防中心（CDC）、世界衛生組織（WHO）、歐洲疾病預防控制中心（ECDC）、泛美衛生署等機構的指導意見正日益影響著患者的決策，尤其是在那些強制要求提交黃熱病國際免疫證書（IVV）的目的地，以及那些蚊媒、食源性、呼吸道和水源感染疾病風險的水源性和水源感染。

人工智慧對旅行疫苗的累積影響

人工智慧 (AI) 並非取代臨床判斷，而是成為旅遊醫學中實用的輔助工具。 AI 工具可以整合並分析行程細節、停留時間、季節性、住宿設施類型、計劃活動、患者年齡、懷孕狀況、免疫狀況、既往病歷和疫苗接種記錄，從而識別所需的疫苗和接種時間限制。這有助於更準確地進行分診，並降低遺漏需要多次接種疫苗或針對臨時出行旅客的接種建議的可能性。

關於旅行疫苗的關鍵區域性見解

亞太地區是旅遊疫苗接種最為活躍的地區之一，這得益於其龐大的國際旅行市場、區域內較高的人口流動性、熱帶疾病的高風險暴露以及中產階級對預防性醫療保健日益成長的需求。該地區還包括一些目的地，旅客可能需要就日本腦炎、傷寒、甲型肝炎、狂犬病、特定環境下的霍亂風險以及常規免疫接種更新等問題進行諮詢。北美地區仍然是旅遊健康管理的重要區域，擁有完善的旅遊醫學基礎設施、廣泛採用美國疾病管制與預防中心（CDC）和國家指南、完善的藥房疫苗接種服務，以及大量的休閒、教育、商務和探親訪友的旅客。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東協的需求主要受頻繁的區域內人員流動、旅遊業復甦、勞動力流動以及特定環境下感染日本腦炎、傷寒、甲型肝炎和狂犬病等疾病的風險驅動，因此，基於行程的諮詢服務至關重要。海灣合作理事會（GCC）國家具有重要的戰略意義，這得益於其朝聖管理、國際勞動力流動、作為航空樞紐的互聯互通以及對數位化醫療保健系統的投資，這些系統能夠支持疫苗接種記錄和旅客合規性。歐盟擁有完善的監管和公共衛生體系，其旅遊建議深受各國機構、歐洲疾病預防控制中心（ECDC）的監測、跨境衛生合作以及高國際旅行率的影響。

重點國家優先旅行疫苗市場洞察。

在美國，疾病管制與預防中心（CDC）關於「旅行者健康」的建議、大規模的國際旅行者、留學計畫、商務旅行以及藥房疫苗接種機會的增加，都支撐了旅行疫苗的需求。在加拿大，聯邦和省級公共衛生指南、完善的旅行者診所網路以及大量的國際休閒旅行者也帶來了類似的需求。同時，在墨西哥和巴西，國內旅遊、商務旅行、區域間旅行以及特定地區對黃熱病和其他熱帶疾病的擔憂，都影響著疫苗需求。英國、德國、法國、義大利和西班牙仍然是歐洲主要的旅遊疫苗市場，這得益於旺盛的國際旅遊需求、商務旅行、成熟的醫療保健體係以及完善的公共衛生指南（支持行前諮詢）。

為旅行醫學領域的領導者提供的實用建議

產業領導者應優先建立一套統一的旅行健康護理流程，從旅行計畫階段開始，一直延續到旅行後的追蹤階段。診所應規範基於行程的風險評估，及時了解權威機構發布的最新指南，並利用電子提醒來提高多劑次疫苗接種的完成率，例如甲型肝炎、乙型肝炎、狂犬病和日本腦炎疫苗等。

旅行疫苗分析的調查方法

本執行摘要採用三角測量研究途徑編寫，整合了公共衛生指南、監管資訊、監測更新、旅遊趨勢指標和產業實踐分析。主要參考類別包括世界衛生組織疾病和免疫指南、美國疾病管制與預防中心旅行者健康建議、歐洲疾病預防控制中心和泛美衛生組織監測資料、國家免疫政策、疫苗附加檔資訊、《國際衛生條例》的要求以及經認可的航空和旅遊旅行指標。

結論：旅行疫苗的戰略展望

隨著全球旅行的活性化、人們對感染疾病疫情的認知不斷提高以及對預防性醫療保健的期望持續高漲，旅行疫苗預計將繼續保持其戰略重要性。市場需求將集中在那些能夠將可靠的臨床指導與便捷的獲取途徑、數位化文件、完善的庫存管理以及基於旅行行程並符合權威公共衛生指南的個人化建議相結合的機構。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 旅行疫苗市場：依疫苗類型分類

  • 常規免疫接種疫苗
    • 甲型肝炎
    • B型肝炎
    • 脊髓灰質炎
    • 麻疹、腮腺炎和德國德國麻疹（MMR）
  • 旅行專用疫苗
    • 黃熱病
    • 傷寒
    • 霍亂
    • 日本腦炎
    • 狂犬病

第8章：旅行疫苗市場：依形式分類

  • 注射藥物
  • 口服

第9章：旅行疫苗市場：依年齡層別分類

  • 成人
  • 兒童
  • 老年人

第10章：旅行疫苗市場：依最終用戶分類

  • 醫院和診所
  • 網路藥房
  • 藥局
  • 旅行診所

第11章 旅行疫苗市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：旅行疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 旅行疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Bio-Manguinhos
  • Bio-Med（P）Limited
  • Biological E Limited
  • Cadila Pharmaceuticals Limited
  • CSL Limited
  • Dano Vaccines & Biologicals Private Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Incepta Pharmaceuticals Ltd.
  • Indian Immunologicals Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Perusahaan Umum（Persero）Bio Farma
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-0316851957A3

The Travel Vaccines Market is projected to grow by USD 10.53 billion at a CAGR of 9.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.65 billion
Estimated Year [2026] USD 6.16 billion
Forecast Year [2032] USD 10.53 billion
CAGR (%) 9.29%

Travel vaccines are a critical preventive-health category for travel clinics, hospitals, occupational health providers, and pharmacy-based immunization programs. Demand is shaped by the recovery of international mobility, destination-specific disease exposure, changing entry requirements, and improved consumer awareness of vaccine-preventable diseases such as yellow fever, typhoid, hepatitis A, hepatitis B, Japanese encephalitis, rabies, meningococcal disease, cholera, and seasonal influenza.

For care delivery organizations, the strongest opportunity is no longer limited to administering vaccines before departure. High-performing providers are building end-to-end travel medicine services that combine itinerary-based risk assessment, vaccine history review, digital reminders, documentation support, adverse event monitoring, and post-travel care pathways. This integrated model improves patient adherence and creates a defensible position in a market where convenience, clinical accuracy, cold-chain reliability, and verified guidance from recognized public health authorities are essential.

Transformative Shifts in the Travel Vaccines Landscape

The travel vaccines landscape is being reshaped by the normalization of international travel after pandemic-era disruptions, stronger border health surveillance, and greater attention to outbreaks that can spread across regions through mobility networks. Guidance from organizations such as the CDC, WHO, ECDC, PAHO, and national health ministries increasingly influences patient decision-making, especially for destinations with International Certificate of Vaccination or Prophylaxis requirements for yellow fever or elevated risk of mosquito-borne, foodborne, waterborne, and respiratory infections.

Travel clinics are also adapting to consumer expectations for faster access and clearer documentation. Online appointment scheduling, pharmacist-led vaccination in many jurisdictions, electronic vaccine records, and bundled pre-travel consultations are shifting the competitive basis from product availability alone to service quality, trusted clinical interpretation, and timely compliance with destination-specific health requirements.

Cumulative Impact of Artificial Intelligence on Travel Vaccines

Artificial intelligence is becoming a practical enabler for travel medicine rather than a replacement for clinical judgment. AI-supported tools can synthesize itinerary details, duration of stay, seasonality, accommodation type, planned activities, patient age, pregnancy status, immune status, medical history, and prior immunization records to flag vaccine needs and timing constraints. This supports more consistent triage and reduces missed recommendations for multi-dose schedules and last-minute travelers.

AI also improves operational performance by forecasting clinic demand around school breaks, religious pilgrimage seasons, business travel cycles, study-abroad periods, and outbreak-related surges. When integrated with cold-chain inventory systems, electronic health records, and pharmacovigilance workflows, AI can reduce waste, improve appointment capacity, support recall systems, and accelerate detection of safety signals while keeping licensed clinicians responsible for final recommendations and informed consent.

Key Regional Insights for Travel Vaccines

Asia-Pacific represents one of the most dynamic regions for travel vaccines because it combines major outbound travel markets, high intraregional mobility, tropical disease exposure, and growing middle-class demand for preventive care. The region also includes destinations where travelers may require counseling on Japanese encephalitis, typhoid, hepatitis A, rabies, cholera risk in specific settings, and routine immunization updates. North America remains a high-value travel health environment due to mature travel medicine infrastructure, CDC and national guidance adoption, strong pharmacy vaccination channels, and large volumes of leisure, education, business, and visiting-friends-and-relatives travel.

Latin America presents mixed demand drivers, including tourism, business travel, ecotourism, and yellow fever risk in selected areas, with PAHO and national health authority updates playing an important role in traveler counseling. Europe benefits from established public health agencies, high outbound travel frequency, structured vaccination guidance across national systems, and strong demand for documentation-ready pre-travel services. The Middle East is shaped by pilgrimage travel, expatriate labor flows, and aviation hub connectivity, with meningococcal vaccination for Hajj and Umrah remaining a highly visible requirement under Saudi health regulations. Africa continues to require close attention because of yellow fever-endemic areas, meningitis belt considerations, malaria prevention needs, and uneven vaccine access, making reliable travel health counseling essential for inbound and outbound travelers.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is supported by dense regional travel, tourism recovery, labor mobility, and exposure to diseases such as Japanese encephalitis, typhoid, hepatitis A, and rabies in specific settings, making itinerary-specific counseling highly relevant. GCC countries are strategically important because of pilgrimage management, international workforce mobility, aviation hub connectivity, and investment in digitally enabled healthcare systems that can support vaccine documentation and traveler compliance. The European Union offers a sophisticated regulatory and public health environment where travel advice is strongly influenced by national institutes, ECDC surveillance, cross-border health coordination, and high outbound mobility.

BRICS countries are important both as outbound travel sources and as vaccine manufacturing, procurement, and immunization-policy stakeholders, particularly across China, India, Brazil, Russia, and South Africa. G7 markets drive premium travel medicine demand through high international travel volumes, strong public health literacy, mature clinical delivery networks, and established private-pay or reimbursement pathways in selected systems. NATO countries add an occupational and defense-health dimension, where deployment readiness, rapid documentation, standardized immunization records, and protection against region-specific pathogens are operational priorities for military, contractor, and humanitarian mobility.

Key Country Insights for Priority Travel Vaccine Markets

In the United States, travel vaccine demand is supported by CDC Travelers' Health recommendations, large outbound travel volumes, study-abroad programs, employer travel, and expanding pharmacy access. Canada shows similar demand through federal and provincial public health guidance, strong travel clinic networks, and high outbound leisure travel, while Mexico and Brazil are influenced by domestic tourism, business travel, regional mobility, and yellow fever or other tropical disease considerations in selected areas. The United Kingdom, Germany, France, Italy, and Spain remain major European travel vaccine markets because of high outbound tourism, business mobility, mature healthcare systems, and established public health guidance that supports pre-travel consultation.

Russia presents a distinct travel health environment influenced by regional mobility, public-sector healthcare structures, and outbound travel to Asia, the Middle East, and Europe. China and India are major growth-oriented travel health markets because of large populations, rising outbound travel, expanding private healthcare access, and increasing awareness of preventive vaccination for education, work, pilgrimage, and tourism. Japan, Australia, and South Korea combine high travel intensity with strong public health literacy, digital health adoption, and structured vaccine documentation practices, making them attractive markets for digital pre-travel counseling, reminder systems, and evidence-based travel immunization services.

Actionable Recommendations for Travel Health Leaders

Industry leaders should prioritize integrated travel health pathways that begin at trip planning and continue through post-travel follow-up. Clinics should standardize itinerary-based risk assessment, maintain current guidance from recognized authorities, and use electronic reminders to improve multi-dose series completion for vaccines such as hepatitis A/B, rabies pre-exposure prophylaxis, and Japanese encephalitis where appropriate.

Providers should also strengthen cold-chain governance, reduce stockouts through demand forecasting, and partner with employers, universities, travel agencies, airlines, insurers, and community pharmacies to reach travelers earlier. Clear patient education is essential: recommendations must explain destination risk, vaccine timing, certificate requirements, contraindications, coadministration considerations, and the continued need for non-vaccine prevention such as mosquito avoidance, food and water precautions, traveler's diarrhea preparation, and malaria chemoprophylaxis when indicated.

Research Methodology for Travel Vaccines Analysis

This executive summary is developed using a triangulated research approach that integrates public health guidance, regulatory sources, surveillance updates, travel trend indicators, and industry practice analysis. Core reference categories include WHO disease and immunization guidance, CDC Travelers' Health recommendations, ECDC and PAHO surveillance resources, national immunization policies, vaccine labeling information, International Health Regulations requirements, and aviation or tourism mobility indicators from recognized institutions.

The methodology emphasizes verified evidence, cross-source validation, and practical market interpretation. Disease risk, vaccine eligibility, regional demand drivers, access dynamics, and service delivery trends are assessed through a combination of epidemiological relevance, traveler behavior, healthcare delivery capacity, policy requirements, and documented clinical guidance. Insights are written for decision-making and should be paired with jurisdiction-specific clinical guidance before implementation.

Conclusion: Strategic Outlook for Travel Vaccines

Travel vaccines are positioned for sustained strategic importance as global mobility, outbreak awareness, and preventive health expectations continue to rise. Demand will favor organizations that combine trusted clinical guidance with convenient access, digital documentation, reliable inventory, and personalized itinerary-based recommendations aligned with recognized public health guidance.

For providers, success depends on moving beyond transactional vaccination toward comprehensive travel medicine. Organizations that invest in AI-enabled triage, evidence-based counseling, cold-chain resilience, safety monitoring, and partnerships across travel, education, corporate health, pharmacy, and public health ecosystems will be best positioned to meet traveler needs while improving protection against vaccine-preventable diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Travel Vaccines Market, by Vaccine Type

  • 7.1. Routine Vaccines
    • 7.1.1. Hepatitis A
    • 7.1.2. Hepatitis B
    • 7.1.3. Polio
    • 7.1.4. Measles, Mumps, Rubella (MMR)
  • 7.2. Travel-Specific Vaccines
    • 7.2.1. Yellow Fever
    • 7.2.2. Typhoid
    • 7.2.3. Cholera
    • 7.2.4. Japanese Encephalitis
    • 7.2.5. Rabies

8. Travel Vaccines Market, by Form

  • 8.1. Injectable
  • 8.2. Oral

9. Travel Vaccines Market, by Age Group

  • 9.1. Adult
  • 9.2. Pediatric
  • 9.3. Geriatric

10. Travel Vaccines Market, by End User

  • 10.1. Hospitals & Clinics
  • 10.2. Online Pharmacies
  • 10.3. Pharmacies
  • 10.4. Travel Clinics

11. Travel Vaccines Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Travel Vaccines Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Travel Vaccines Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. AstraZeneca PLC
  • 15.3. Bavarian Nordic A/S
  • 15.4. Bharat Biotech International Limited
  • 15.5. Bio-Manguinhos
  • 15.6. Bio-Med (P) Limited
  • 15.7. Biological E Limited
  • 15.8. Cadila Pharmaceuticals Limited
  • 15.9. CSL Limited
  • 15.10. Dano Vaccines & Biologicals Private Limited
  • 15.11. Dynavax Technologies Corporation
  • 15.12. Emergent BioSolutions Inc.
  • 15.13. GlaxoSmithKline plc
  • 15.14. Incepta Pharmaceuticals Ltd.
  • 15.15. Indian Immunologicals Ltd.
  • 15.16. Johnson & Johnson Services, Inc
  • 15.17. Merck & Co., Inc.
  • 15.18. Novartis AG
  • 15.19. Perusahaan Umum (Persero) Bio Farma
  • 15.20. Pfizer Inc.
  • 15.21. Sanofi S.A.
  • 15.22. Serum Institute of India Pvt. Ltd.
  • 15.23. Shenzhen Kangtai Biological Products Co., Ltd.
  • 15.24. Takeda Pharmaceutical Company Limited
  • 15.25. Valneva SE
  • 15.26. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRAVEL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TRAVEL VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ROUTINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ROUTINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ROUTINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEPATITIS A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATITIS A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEASLES, MUMPS, RUBELLA (MMR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEASLES, MUMPS, RUBELLA (MMR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEASLES, MUMPS, RUBELLA (MMR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL-SPECIFIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL-SPECIFIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL-SPECIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL YELLOW FEVER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL YELLOW FEVER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL YELLOW FEVER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYPHOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPHOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYPHOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOLERA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHOLERA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOLERA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JAPANESE ENCEPHALITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JAPANESE ENCEPHALITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JAPANESE ENCEPHALITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAVEL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRAVEL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRAVEL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 120. GCC TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. G7 TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 142. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 143. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NATO TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 148. NATO TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 150. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. RUSSIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. SPAIN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY ROUTINE VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TRAVEL-SPECIFIC VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)